Literature DB >> 6432155

Rifampicin in non-tuberculous infections.

W Brumfitt, J M Hamilton-Miller.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432155      PMCID: PMC1442561          DOI: 10.1136/bmj.289.6443.496

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  9 in total

Review 1.  Adverse reactions to rifampicin in antituberculosis regimens.

Authors:  D J Girling
Journal:  J Antimicrob Chemother       Date:  1977-03       Impact factor: 5.790

2.  Rifampicin hepatitis. A clinical and histological study.

Authors:  P J Scheuer; J A Summerfield; S Lal; S Sherlock
Journal:  Lancet       Date:  1974-03-16       Impact factor: 79.321

3.  Failure to stimulate antibodies in man after 7 days' high-dose treatment with rifampicin.

Authors:  W Brumfitt; J M Hamilton-Miller; A Wood
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

4.  Use of rifampin for the treatment of urinary tract infections.

Authors:  W Brumfitt; S Dixson; J M Hamilton-Miller
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

5.  Evidence that rifampicin can be used safely for non-tuberculous diseases.

Authors:  G Acocella; W Brumfitt; J M Hamilton-Miller
Journal:  Thorax       Date:  1980-10       Impact factor: 9.139

6.  Hepatotoxicity of the combination of rifampin-ethionamide in the treatment of multibacillary leprosy.

Authors:  S R Pattyn; L Janssens; J Bourland; T Saylan; E M Davies; S Grillone; C Feracci
Journal:  Int J Lepr Other Mycobact Dis       Date:  1984-03

7.  Can rifampicin use be safely extended? Evidence for non-emergence of resistant strains of Mycobacterium tuberculosis.

Authors:  G Acocella; J M Hamilton-Miller; W Brumfitt
Journal:  Lancet       Date:  1977-04-02       Impact factor: 79.321

Review 8.  Adverse effects of rifampin.

Authors:  J Grosset; S Leventis
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

Review 9.  Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review).

Authors:  M Kissling; N Bergamini
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

  9 in total
  1 in total

1.  Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Authors:  Richard E Kast; Nicolas Skuli; Georg Karpel-Massler; Guido Frosina; Timothy Ryken; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2017-06-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.